<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The uncertain risk of secondary <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> (sICH) frequently keeps clinicians from initiating oral anticoagulation (OAC) early after ischemic cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The goal of this experimental study was to determine the risk of sICH depending on the timing of OAC initiation relative to <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> and to address the role of hematogenous macrophages for repair processes preventing OAC-associated sICH </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: C57BL/6 mice were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Subgroups were treated with either the <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> (VKA) <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi> or the direct thrombin inhibitor dabigatran etexilate </plain></SENT>
<SENT sid="4" pm="."><plain>Hematogenous macrophages were depleted using intraperitoneal injections of clodronate-filled liposomes </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Time to therapeutic OAC was 48 hours with VKA and 0.5 hours with dabigatran etexilate treatment </plain></SENT>
<SENT sid="6" pm="."><plain>In VKA-treated mice, the risk of sICH was high if effective OAC was already present at <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> or achieved within 48 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>With more delayed OAC, the risk of sICH rapidly decreased </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with VKA treatment, effective anticoagulation with dabigatran etexilate was associated with a significantly reduced extent of sICH, either if present at <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> or if achieved 48 hours later </plain></SENT>
<SENT sid="9" pm="."><plain>Partial <z:mpath ids='MPATH_63'>depletion</z:mpath> of macrophages greatly increased the extent of OAC-associated sICH in the <z:hpo ids='HP_0011011'>subacute</z:hpo> stage of 3 to 4 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our findings suggest that repair mechanisms involving hematogenous macrophages rapidly decrease the risk of OAC-associated sICH in the first days after <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The lower risk of sICH under dabigatran etexilate compared with VKA treatment may facilitate early initiation of OAC after cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>